Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9637909 | 0.79 | CA1 (0.30) | — | |
| SCHEMBL7772123 | 0.71 | TDP1 (0.34) | — | |
| SCHEMBL638648 | 0.71 | NCF1 (0.36) | — | |
| SCHEMBL23581644 | 0.69 | KDM4E (0.35) | — | |
| SCHEMBL2254293 | 0.68 | ALDH1A1 (0.34) | — | |
| SCHEMBL3919235 | 0.67 | ERN1 (0.38) | ERN1 | |
| SCHEMBL2460080 | 0.67 | ACP1 (0.33) | — | |
| SCHEMBL3288004 | 0.67 | — | — | |
| SCHEMBL2456300 | 0.66 | CYP1A2 (0.31) | — | |
| SCHEMBL294356 | 0.65 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291345-B1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6924276-B2 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | CHEN MICHAEL HUAI GU (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1313694-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | SORENSON RODERICK JOSEPH (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1291345-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002018319-A1 | PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039208-A1 | Process for making n-aryl-anthranilic acids and their derivatives | AADAC, AHR, AADAT | ERN1 4316/4885 |
| US-20030087924-A1 | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP3, MMP9 | ERN1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.